These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36163020)

  • 1. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study).
    Kinoshita T; Shinoda M; Nishizaki Y; Shiraki K; Hirai Y; Kichikawa Y; Tsushima K; Shinkai M; Komura N; Yoshida K; Kido Y; Kakeya H; Uemura N; Kadota J
    BMC Med; 2022 Sep; 20(1):342. PubMed ID: 36163020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19.
    Kim YS; Jeon SH; Kim J; Koh JH; Ra SW; Kim JW; Kim Y; Kim CK; Shin YC; Kang BD; Kang SJ; Park CH; Lee B; Lee JY; Lee CH; Choi JP; Kim JY; Yu SN; Peck KR; Kim SH; Heo JY; Kim HA; Park HJ; Choi J; Han J; Kim J; Kim HJ; Han SH; Yoon A; Park M; Park S; Kim Y; Jung M; Oh MD
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0045222. PubMed ID: 36515544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
    Gunst JD; Staerke NB; Pahus MH; Kristensen LH; Bodilsen J; Lohse N; Dalgaard LS; Brønnum D; Fröbert O; Hønge B; Johansen IS; Monrad I; Erikstrup C; Rosendal R; Vilstrup E; Mariager T; Bove DG; Offersen R; Shakar S; Cajander S; Jørgensen NP; Sritharan SS; Breining P; Jespersen S; Mortensen KL; Jensen ML; Kolte L; Frattari GS; Larsen CS; Storgaard M; Nielsen LP; Tolstrup M; Sædder EA; Østergaard LJ; Ngo HTT; Jensen MH; Højen JF; Kjolby M; Søgaard OS
    EClinicalMedicine; 2021 May; 35():100849. PubMed ID: 33903855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial.
    Tobback E; Degroote S; Buysse S; Delesie L; Van Dooren L; Vanherrewege S; Barbezange C; Hutse V; Romano M; Thomas I; Padalko E; Callens S; De Scheerder MA
    Int J Infect Dis; 2022 Sep; 122():628-635. PubMed ID: 35803469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste.
    Chupp G; Spichler-Moffarah A; Søgaard OS; Esserman D; Dziura J; Danzig L; Chaurasia R; Patra KP; Salovey A; Nunez A; May J; Astorino L; Patel A; Halene S; Wang J; Hui P; Patel P; Lu J; Li F; Gan G; Parziale S; Katsovich L; Desir GV; Vinetz JM
    medRxiv; 2022 Jan; ():. PubMed ID: 35132421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
    Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
    Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
    Jilg N; Chew KW; Giganti MJ; Daar ES; Wohl DA; Javan AC; Kantor A; Moser C; Coombs RW; Neytman G; Hoover K; Jana A; Hart PA; Greninger AL; Szurgot B; Eron JJ; Currier JS; Hughes MD; Smith DM; Li JZ;
    Clin Infect Dis; 2023 Oct; 77(7):941-949. PubMed ID: 37279602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate.
    Hernández-Mitre MP; Morpeth SC; Venkatesh B; Hills TE; Davis J; Mahar RK; McPhee G; Jones M; Totterdell J; Tong SYC; Roberts JA
    Clin Microbiol Infect; 2024 Jun; 30(6):743-754. PubMed ID: 38331253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.